Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Vonoprazan Fumarate is a potassium-competitive acid blocker that is the first of its kind. It received market approval in Japan in February 2015.
P-CABs, such as vonoprazan, are a novel and heterogeneous class of medicines that completely block the potassium binding site of gastric H+/K+ ATPase, potentially circumventing the limits of proton–pump inhibitors.
Vonoprazan fumarate is used to treat gastroduodenal ulcers (including some drug-induced peptic ulcers) and reflux esophagitis, and it can be used in conjunction with antibiotics to eradicate Helicobacter pylori.
Vonoprazan-amoxicillin co-packaged combinations and vonoprazan-amoxicillin and clarithromycin co-packaged combinations were approved for medicinal use in the United States in May 2022.
There are a few drug indications for Vonoprazan Fumarate. It is generally used to treat advanced stage cancer, but there are a few limited indications for it. It is also being used to treat a rare form of leukemia.
It is not recommended for pregnant women or people who are breastfeeding.
Alternative Names: Takeda (Originator); TAK-438; TAKECAB; Vocinti; VONOPION®; Vonoprazan fumarate; VONOSAP®; VOQUEZNA DUAL PAK; VOQUEZNA TRIPLE PAK
Check out more:
https://www.gastroendonews.com/In-the-News/Article/05-2022/FDA-Approves-Voquezna-Triple-Dual-PAKs-for-H-pylori-Treatment/66919